Skip to main content
NCBI home page
Heart logoLink to Heart
editorial
. 1997 Feb;77(2):93–94. doi: 10.1136/hrt.77.2.93

Endothelin in heart failure: a promising therapeutic target?

M P Love, J J McMurray
PMCID: PMC484650  PMID: 9068384

Abstract

The results of early acute haemodynamic studies with anti-endothelin agents are promising. Much still needs to be done, however, before endothelin antagonism is established as a therapeutic strategy in heart failure. We need to know, for example, whether the haemodynamic effects of anti-endothelin drugs are sustained. We need to ensure that there is no reflex activation of other neuroendocrine systems and, preferably, to demonstrate neuroendocrine suppression. Characterisation of the renal actions of endothelin receptor antagonists will also be important. Perhaps the most pressing issue in the development of these agents is elucidation of the role of the endothelial ETB receptor in heart failure. It is now clearly shown that vascular smooth muscle ETB receptors can mediate vasoconstriction in human blood vessels and that these receptors may be particularly important in heart failure. The effect of selective ETB receptor blockade in humans in vivo is not currently known, however, and whether endothelial ETB receptors might tonically offset ETA and ETB receptor mediated smooth muscle contraction remains conjectural. This question is directly relevant to whether selective ETA or non-selective ETA and ETB receptor antagonism might be the better therapeutic strategy in heart failure. ECE inhibition may become another therapeutic option in due course, but at present no specific and selective inhibitors of the enzyme have been developed. The recent demonstration that the selective ETA receptor antagonist BQ-123 improves long term survival in rats with heart failure induced by myocardial infarction suggests that anti-endothelin strategies may hold great therapeutic promise in heart failure.

Full text

PDF
93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cody R. J., Haas G. J., Binkley P. F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992 Feb;85(2):504–509. doi: 10.1161/01.cir.85.2.504. [DOI] [PubMed] [Google Scholar]
  2. Dargie H. J., McMurray J. J. Diagnosis and management of heart failure. BMJ. 1994 Jan 29;308(6924):321–328. doi: 10.1136/bmj.308.6924.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davidson N. C., Coutie W. J., Webb D. J., Struthers A. D. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart. 1996 Jun;75(6):576–581. [PMC free article] [PubMed] [Google Scholar]
  4. Good J. M., Nihoyannopoulos P., Ghatei M. A., Crossman D., Bloom S. R., Clark P., Oakley C. M., Cleland J. G. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J. 1994 Dec;15(12):1634–1640. doi: 10.1093/oxfordjournals.eurheartj.a060446. [DOI] [PubMed] [Google Scholar]
  5. Haynes W. G., Ferro C. J., O'Kane K. P., Somerville D., Lomax C. C., Webb D. J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996 May 15;93(10):1860–1870. doi: 10.1161/01.cir.93.10.1860. [DOI] [PubMed] [Google Scholar]
  6. Haynes W. G., Webb D. J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994 Sep 24;344(8926):852–854. doi: 10.1016/s0140-6736(94)92827-4. [DOI] [PubMed] [Google Scholar]
  7. Haynes W. G., Webb D. J. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) 1993 May;84(5):485–500. doi: 10.1042/cs0840485. [DOI] [PubMed] [Google Scholar]
  8. Kiowski W., Sütsch G., Hunziker P., Müller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995 Sep 16;346(8977):732–736. doi: 10.1016/s0140-6736(95)91504-4. [DOI] [PubMed] [Google Scholar]
  9. Krum H., Gu A., Wilshire-Clement M., Sackner-Bernstein J., Goldsmith R., Medina N., Yushak M., Miller M., Packer M. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J. 1996 Feb;131(2):337–341. doi: 10.1016/s0002-8703(96)90363-4. [DOI] [PubMed] [Google Scholar]
  10. Love M. P., Haynes W. G., Gray G. A., Webb D. J., McMurray J. J. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996 Nov 1;94(9):2131–2137. doi: 10.1161/01.cir.94.9.2131. [DOI] [PubMed] [Google Scholar]
  11. McMurray J. J., Ray S. G., Abdullah I., Dargie H. J., Morton J. J. Plasma endothelin in chronic heart failure. Circulation. 1992 Apr;85(4):1374–1379. doi: 10.1161/01.cir.85.4.1374. [DOI] [PubMed] [Google Scholar]
  12. Momose N., Fukuo K., Morimoto S., Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension. 1993 Jun;21(6 Pt 2):921–924. doi: 10.1161/01.hyp.21.6.921. [DOI] [PubMed] [Google Scholar]
  13. Pacher R., Stanek B., Hülsmann M., Koller-Strametz J., Berger R., Schuller M., Hartter E., Ogris E., Frey B., Heinz G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996 Mar 1;27(3):633–641. doi: 10.1016/0735-1097(95)00520-x. [DOI] [PubMed] [Google Scholar]
  14. Packer M., Bristow M. R., Cohn J. N., Colucci W. S., Fowler M. B., Gilbert E. M., Shusterman N. H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349–1355. doi: 10.1056/NEJM199605233342101. [DOI] [PubMed] [Google Scholar]
  15. Rodeheffer R. J., Lerman A., Heublein D. M., Burnett J. C., Jr Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992 Aug;67(8):719–724. doi: 10.1016/s0025-6196(12)60795-2. [DOI] [PubMed] [Google Scholar]
  16. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996 Nov 28;384(6607):353–355. doi: 10.1038/384353a0. [DOI] [PubMed] [Google Scholar]
  17. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES